High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer

Mollavelioglu, Baran; Cetin Aktas, Esin; Cabioglu, Neslihan; Abbasov, Aykhan; Onder, Semen; Emiroglu, Selman; Tükenmez, Mustafa; Muslumanoglu, Mahmut; Igci, Abdullah; Deniz, Gunnur; Ozmen, Vahit

doi:10.1186/s12957-022-02810-z

Table 5 Demographic, clinical, and pathological features and ICR expressions on tumor-infiltrating CD16^-CD56^bright NK cell subset

From: High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer

	PD-1⁺ NK cells		CTLA-4⁺ NK cells		TIGIT⁺ NK cells		LAG-3⁺ NK cells		TIM-3⁺ NK cells
	Median (min–max)	p	Median (min–max)	p	Median (min–max)	p	Median (min–max)	p	Median (min–max)	p
Age
≤ 50 (n:18)	13 (1.5–74)	0.7	16 (1.8–80)	0.95	7.5 (1–60)	0.64	6.1 (0.1–67)	0.38	21 (1–71)	0.83
> 50 (n:14)	15.5 (2–35)	0.7	23.5 (1.3–80)	0.95	10.5 (0–60)	0.64	25 (0–70)	0.38	22 (0.4–48)	0.83
Menopausal status
Pre (n:17)	20 (1,5–74)	0.97	24 (1.8– 80)	0.28	9 (1.2–60)	0.86	11 (0,1–68)	0.86	24 (1–71)	0.97
Post (n:15)	11 (2–35)	0.97	15 (1.3–62)	0.28	10 (0–60)	0.86	22 (0–70)	0.86	21 (0.4–48)	0.97
HER-2
Negative (n:21)	11 (1.5–74)	0.49	15 (1.3–80)	0.17	6 (0–60)	0.30	6 (0–50)	0.05	20 (0.4–48)	0.14
Positive (n:11)	20 (1.7–56)	0.49	30 (1.8–80)	0.17	11 (2–59)	0.30	27 (0.3–70)	0.05	32 (1–71)	0.14
Ki-67
≤ 20 (n:5)	6 (1.7–56)	0.58	18 (1.8–65)	0.83	10 (0–35)	0.67	25 (0–70)	0.83	21 (1–71)	0.69
> 20 (n:27)	20 (1.5–74)	0.58	17 (1.3–80)	0.83	10 (0.3–60)	0.67	11 (0.1–68)	0.83	23 (0.4–48)	0.69
Histologic grade
Grade 2 (n:10)	15.5 (1.7–74)	0.90	29.5 (1.8–80)	0.10	8 (0–48)	0.77	19.5 (0–67)	0.72	24.5 (1–71)	0.45
Grade 3 (n:22)	13 (1.5–35)	0.90	13.5 (1.3–80)	0.10	10 (0.3–60)	0.77	11 (0.1–70)	0.72	17 (0,4–48)	0.45
High TIL density (>%10)
Negative (n:20)	15.5 (1.5–74)	0.96	21 (1.5–80)	0.93	7.7 (0–60)	0.47	12.5 (0–70)	0.74	23 (0.4–71)	0.95
Positive (n:12)	13 (2–35)	0.96	14.4 (1.3–41)	0.93	15 (1.2–60)	0.47	16.5 (0.1–32)	0.74	20.5 (1.7–48)	0.95
Luminal
Negative (n:6)	13 (2–56)	0.80	24.5 (8.3–80)	0.25	22.5 (1.2–51)	0.61	17 (0.1–68)	0.59	27.5 (4–71)	0.56
Positive (n:26)	15.5 (1.5–74)	0.80	17.5 (1.3–80)	0.25	9.5 (0–60)	0.61	12.5 (0–70)	0.59	20.5 (0.4–48)	0.56
T stage
T1 (n:9)	6 (1.7–35)	0.45	13.1 (1.3–80)	0.60	26 (1.3–60)	0.26	28 (0.3–70)	0.12	18 (1–48)	0.58
T2 (n:23)	16 (1.5–74)	0.45	24 (1.5–80)	0.60	9 (0–60)	0.26	11 (0–67)	0.12	23 (0.4–71)	0.58
N stage
N0 (n:23)	10 (1.5–74)	0.34	13.8 (1.3–80)	0.27	11 (0–60)	0.45	25 (0–70)	0.35	20 (0.4–71)	0.58
N1 (n:9)	20 (3.2–35)	0.34	30 (6–62)	0.27	6 (1.3–60)	0.45	11 (1.5–25)	0.35	24 (3.4–45)	0.58
Lympho-vascular invasion
Negative (n:16)	6.5 (2–74)	0.28	16 (1.3–80)	0.47	7.5 (0–60)	0.45	8.6 (0–70)	0.48	23.5 (0.4–45)	0.92
Positive (n:16)	21 (1.5–56)	0.28	27 (1.8–80)	0.47	10.2 (1.2–60)	0.45	21.5 (0.1–68)	0.48	18.5 (1–71)	0.92
Extensive intraductal component
Negative (n:21)	10 (1.7–74)	0.63	18 (1.5–80)	0.73	5.4 (0–60)	0.24	11 (0–70)	0.55	20 (0.4–48)	0.42
Positive (n:11)	16 (1.5–56)	0.63	15 (1.3–80)	0.73	10.3 (1–59)	0.24	25 (0.4–68)	0.55	23 (1.7–71)	0.42

Back to article page

ISSN: 1477-7819

Contact us

General enquiries: journalsubmissions@springernature.com

World Journal of Surgical Oncology

Contact us